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Linkage disequilibrium? Synonymous SNPs? Single hap-
lotype? Synergistic epistasis? Hierarchisation clustering?
Allelic recombination? Do those terms mean anything to
you? If not, you had better learn the (genetic) language
(quickly)! Come on, it is not more complicated than
cytokine networks, or diagrams showing intracellular
signaling pathways. . . These terms are invading our
journals dedicated to intensive care in so-called genomics
studies [1]. Systems biology is another new term for a field
integrating genomics, proteomics and bioinformatics.
It is important to differentiate between various types of
genetic studies. Genetic studies can be done without the
use of gene sequencing, and can be based on mendelian
genetics, investigations in families with a particular phe-
notype, or in homozygous twins. Genomic studies usually
have to do with mapping a trait, a small variation in the
sequence of our genome (polymorphism), identifying
groups of individuals who share a given polymorphism,
predisposing for diseases or for a particular outcome when
the disease occurs. Even before the human genome had
been deciphered in 2003, it became evident that small
variations existed in the genetic code between individuals.
These polymorphisms correspond, for example, to a sin-
gle nucleotide modification in the coding or non-coding
region of a gene (single nucleotide polymorphisms, SNPs);
others are insertions or deletions of a few nucleotides
or repeated sequences. While most of these variations
remain “silent”, some of them have a significant effect
on levels of protein expression and/or protein function.
Human polymorphism databases now exist and are fed
daily by new knowledge on those small variations linked
to diseases [2]. For genomic studies to be insightful they
usually need to be performed on a very large number
of subjects and patients (of the same ethnic descent).
Only a powerful statistical analysis is able to link genetic
variations and the appearance of a disease or an increased
disease severity [3]. One of the first and classical examples
of this type of study in critical care is a SNP found in the
promoter region of the tumor necrosis factor (TNF)-α gene
promoter region, associated with increased TNF-α pro-
duction, which determines both susceptibility and severity
of sepsis [4]. Pharmacogenomics is one particular aspect
of genomics. It refers to the study of genetic determinants
causing variability of drug responses. Cytochromes and
other enzymes responsible for drug metabolism, as well as
drug target proteins or carriers, are sometimes very poly-
morphic in a given population. This largely determines
responses to therapy, and partly explains individual vari-
ability of drug responsiveness. Soon, convenient and rapid
genomic assays will be available in critically ill patients
guiding the clinician in his therapeutic decisions [5].
Pharmacogenomic analyses will also be incorporated in
clinical trials as a means to select adequate populations of
patients likely to benefit from a given drug [6].
Another exciting development of systems biology
is the study of variations in the expression of genes
and proteins in a population of patients or in a disease
(“functional genomics”). Only a minor part of the genome
is transcribed into messenger RNA (mRNA, “transcrip-
tome”), and translated into proteins (“proteome”). The
process from gene activation to protein synthesis is
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complex and depends largely on transcription factors
binding to promoter regions of genes. The analysis of the
transcriptome is usually done using microarrays. Com-
plementary DNA made from tissue mRNA is hybridized
with oligonucleotide probes corresponding to known
transcripts immobilized on a chip. Modern chips span
the whole transcriptome of a species; 54,000 probes can
now be immobilized on a chip allowing to interrogate
the whole human transcriptome on a single chip, for
example. Alternatively, arrays can be customized to fit
a subset of genes of interest (e.g. cancer and immunity).
Levels of transcription are usually compared between two
conditions (normal vs. disease, early vs. late, survivors
vs. non-survivors, etc.). Transcriptomics also offer the
exciting possibility of defining gene expression signa-
tures specific for a given disease or condition [7]. It is
possible, for example, to differentiate SIRS from sepsis
using leukocyte gene expression profiles [8, 9], as well
as the family of bacteria responsible for sepsis [10], and
soon will be possible with the bacteria itself [11]. In
other words, a patient will soon be identified at the time
of admission as having a Gram-negative sepsis due to
E.coli, based on a pattern (or cluster) of genes specific to
sepsis and a detection of the causative microorganism by
molecular techniques.
Post-transcriptional modifications, such as mRNA sta-
bilization, also play a crucial role for protein expression.
Cell mRNA levels, and hence protein production, depend
on both the level of transcription and mRNA stability. The
function of newly synthesized proteins is also highly de-
pendent on post-translational modifications; these include,
for example, protein phosphorylation, oxidation and add-
ition of lipids, depending on the state of cell activation,
and not on transcription per se. Although proteomic tech-
niques have recently progressed, the detection of low levels
of proteins in a cell lysate or in a given body fluid remains
difficult. In addition, automatization and standardization
of proteomic techniques are problematic and warrant their
use in the clinical setting for the time being.
In this issue of “Intensive Care Medicine” Payen et al.
describe their work in which they have sampled circulat-
ing leukocytes in a series of patients admitted for septic
shock and during their recovery phase [12]. They meas-
ured levels of expression of 340 genes during the course
of septic shock using a microarray dedicated to inflamma-
tion, and compared them with their respective expression
at the time of admission. They found significant modifica-
tions in transcript levels of ten genes between day 0, day 7
and day 28 for survivors. Of these ten genes, they con-
firmed significant variations by PCR in 4 mRNAs, and by
ELISA for one of these proteins. One of the mRNA iden-
tified was the invariant chain [CD74, a major histocompa-
tibility complex (MHC) class-II-associated protein]. CD74
mRNA levels were downregulated at the time of admission
compared with levels found later in the course of sepsis.
CD74 mRNA levels correlated with the monocyte surface
expression of the MHC class-II HLA-DR molecule in the
same patients. This suggested that a decreased CD74 ex-
pression played a role in the low-monocyte HLA-DR ex-
pression observed early during sepsis.
Two transcripts significantly decreased during the
course of septic shock: S100A8 and S100A12 mRNAs,
encoding for calcium-binding proteins also know as
calgranulin A and C, respectively. Plasma S100A8 protein
levels decreased in the 14 survivors, but not in the 3 pa-
tients who died. S100A8 is physiologically concentrated
in phagocytic granules from granulocytes and released at
sites of inflammation. It carries pro-inflammatory effects
when complexed with its S100A9 companion, most likely
via an interaction with the Toll-like receptor 4/MD-2
complex and/or the receptor for advanced glycation
end-products (RAGE) [13]. This mode of action is remi-
niscent of that of the high-mobility group box 1 (HMGB1)
alarmin [14]. S100 proteins also carry prothrombotic
effects and induce increased vascular permeability, two
essential features of septic shock. Interestingly, mice
lacking the S100A8 protein are protected against lethal
septic shock [15]. S100A8, A9 and A12 proteins qualify
as endogenous “alarmins” secreted by immune effector
cells, signaling danger in the context of tissue suffering
and inflammation [14]. Further studies on S100 proteins
and alarmins are necessary to identify their possible
pathogenic role in human sepsis and in diseases associated
with a systemic inflammatory syndrome and multiple
organ dysfunction [16].
This study has limitations. Firstly, although the number
of genes studied seems significant (n = 340), it represents
less than 1% of the human transcriptome. In spite of the
fact that the chip used was well designed to study genes
of interest in sepsis, it remains a possibility that impor-
tant variations in unsuspected gene transcripts were missed
with this analysis. Secondly, the study was performed on
a limited number of patients with an abdominal source of
infection as the cause for septic shock. Thirdly, gene profil-
ing was done on a mixed cell population including mono-
cytes, lymphocytes and immature neutrophils. The cellular
source of the transcripts studied by Payen et al. [12] can
therefore not be identified precisely. In addition, mature
neutrophils were kept out of the analysis, and are likely to
be an important source of S100 proteins. Finally, a limita-
tion inherent to all of these types of studies is that the cut-
off value used to decide whether a variation in transcript
level is significant or not (usually twofold increase or de-
crease) is purely arbitrary. A 20% increase in transcription
may represent a very significant variation for some genes,
and will be overseen by classical transcriptomic analyses.
Moreover, variations in mRNA levels do not always mean
increased or decreased gene transcription, and do not al-
ways parallel protein production, as discussed previously.
Will genomic studies replace more classical research,
i.e. the step-to-step study of one gene and the function of
one protein in a given disease? It is very unlikely. Radio
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has not replaced newspapers, and television has replaced
neither radio nor newspapers. At some point, someone has
to go to the bench and study that particular gene that has
been identified in a transcriptomic experiment, and figure
out in what exactly this gene is involved. Systems biol-
ogy is very complementary to basic research. It represents
a perfect interface, reinforces translational research, where
the need for the clinical and basic research worlds to ex-
change ideas, concepts and visions is so important.
Genomics has already entered the clinical arena in
oncology and is used daily for selecting patients for
treatments, for example. Will the intensivist soon become
a “gene profiler”? We are not quite there yet. We need to
prepare ourselves, however, by learning the language and
understanding the technology. While genomic analyses are
at the door of our ICUs, in particular pharmacogenomics,
it is generally accepted that transcriptomic and proteomic
studies are still investigational tools. The analysis of
the complete transcriptional network of immune cell
activation has reached a very high level of complexity, as
recently shown by Calvano et al. in volunteers injected
with endotoxin [17]. One of the important messages of
this paper is that researchers focused on “their gene”
should broaden their views and integrate their gene into
this complex network. Another crucial result from these
studies was the identification of a dysregulation of leuko-
cyte bioenergetics induced by endotoxin, which makes
a lot of sense for the clinician caring for septic patients.
Systems biology provides invaluable results and leads the
way to the identification of new markers, new mediators,
new pathways, and potentially new therapeutic targets to
combat deadly syndromes such as septic shock.
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